BioSpace News Archive

Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results.

Incyte Corporation today announced the appointment of Jacqualyn Fouse, Ph.D., as a new member of the Board of Directors, effective November 14, 2017.

Of the 19 patients implanted in The INSPIRE Study to date, 16 patients are in follow-up, 14 of whom have reached the six-month primary endpoint visit.

During the period to September 30, 2017, Theradiag generated consolidated revenues of €6.8 million, up +7% compared with 2016.

The Company will conduct an earnings call at 8:00 am EST on Wednesday, November 8, 2017, where senior management will discuss the Company’s performance and answer questions from participants.

Revenues for the third quarter of 2017 decreased three percent to $44M, compared to $45.3M for the third quarter of 2016.

AcelRx today announced that it will release third quarter financial results after market close on Thursday, November 9th.

Impax announced today the commencement of a consent solicitation with respect to its 2.00% Convertible Senior Notes due 2022.

Sales in the first six months of FY2017 decreased by 1.8% compared to those in the corresponding period of the previous fiscal year (“year-on-year”) to JPY639.8 billion due to the impact of certain items such as the transfer of the global dermatology business in April 2016 and the transfer of long-listed products in Japan in April 2017.

The Company reported significant changes to the Consolidated Statements of Financial Position, including an increase in total assets of $6,111,470 from $1,003,682 in 2016 to $7,115,152 in 2017.